Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 6, 2004, Pages 1134-1138

  Thibault, F M ^a   Hernandez, E ^b   Vidal, D R ^a   Girardet, M ^b   Cavallo, J D ^b  

^a CENTRE DE RECHERCHES   (France)

^b centre hospitalier de Chaumont   (France)

Author keywords

Biowarfare; Glanders; Melioidosis; MICs; Resistance

Indexed keywords

AGAR; AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFSULODIN; CEFTAZIDIME; CIPROFLOXACIN; DOXYCYCLINE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; NALIDIXIC ACID; NETILMICIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CONTROLLED STUDY; CULTURE MEDIUM; GRAM NEGATIVE INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL WARFARE; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; DRUG RESISTANCE, BACTERIAL; GLANDERS; HORSE DISEASES; HORSES; HUMANS; MELIOIDOSIS; MICROBIAL SENSITIVITY TESTS; RATS;

EID: 12344260650     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh471     Document Type: Article

References (12)

1. White, N. J. (2003). Melioidosis. Lancet 361, 1715-22.
2. Neubauer, H., Meyer, H. & Finke, E. J. (1997). Human glanders. International Review of Armed Forces Medical Services 70, 258-65.
3. Centers for Disease Control and Prevention. (2003). Bioterrorism Agents/Diseases. [Online.] http://www.bt.cdc.gov/agent/agentlist-category.asp (6 September 2004, date last accessed)
4. Heine, H. S., England, M. J., Waag, D. M. et al. (2001). In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test. Antimicrobial Agents and Chemotherapy 45, 2119-21.
5. Dance, D., Wuthiekanun, V., Chaowagul, W. et al. (1989). The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. Journal of Antimicrobial Chemotherapy 24, 295-309.
6. Batmanov, V. P. (1994). Sensitivity of Pseudomonas mallei to tetracyclines and their effectiveness in experimental glanders. Antibiotiki I Khimioterapiia 39, 33-7.
7. Kenny, D. J., Russell, P., Rogers, D. et al. (1999). In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp. Antimicrobial Agents and Chemotherapy 43, 2773-5.
8. Ashdown, L. R. (1979). Identification of Pseudomonas pseudomallei in the clinical laboratory. Journal of Clinical Pathology 32, 500-4.
9. European Agency for the Evaluation of Medicinal Products. (2002). Guidance document on use of medicinal products for treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism. [Online.] http://www.emea.eu.int/pdfs/human/bioterror/404801.pdf (9 September 2004, date last accessed).
10. Russell, P., Eley, S. M., Ellis, J. et al. (2000). Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. Journal of Antimicrobial Chemotherapy 45, 813-8.
11. Chetchotisakd, P., Chaowagul, W., Mootsikapun, P. et al. (2001). Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. American Journal of Tropical Medicine and Hygiene 64, 24-7.
12. Moore, R. A., DeShazer, D., Reckseidler, S. et al. (1999). Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrobial Agents and Chemotherapy 43 465-70.